Abiraterone
- BNF:
- 8.3.4
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- July 2012
Comments
RED
- NICE TA259: Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy). Abiraterone – a recommended option for metastatic prostate cancer after testosterone reduction therapy and docetaxel. NHSE commissioned. (Decision date - July 2012)
- NICE TA387: for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. NHSE commissioned. (Decision date - May 2016)
DO NOT PRESCRIBE (DNP)
- NICE TA721 - Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. (Decision date - September 2021)
Black Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again